Drug Trial Radar · NCT03471988
Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis
Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Apr 16, 2018
Primary completion
Apr 21, 2021
Study completion Apr 21, 2021
Sponsor
- Lead sponsor
- Asahi Kasei Therapeutics CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).
Conditions
- Deep Mycosis
Interventions
AK1820Drug
Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible. 372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole. Other Names: Cresemba, BAL8557
VoriconazoleDrug
Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible. Other Name : VFend
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with adverse events between the first administration of investigational product and the end of Follow-up.Time frame: From the first study drug administration until 28 days after the last dose of study drug (up to approximately Day 112).
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Research site
Chiba, Japan
Research site
Ibaraki, Japan
Research site
Nagasaki, Japan
Research site
Nagakute, Aichi-ken, Japan
Research site
Nagoya, Aichi-ken, Japan
Research site
Seto, Aichi-ken, Japan
Research site
Higashiku, Fukuoka, Japan
Research site
Minamiku, Fukuoka, Japan
Research site
Nagara, Gifu, Japan
Research site
Naka-Ku, Hiroshima, Japan
Research site
Asahikawa, Hokkaido, Japan
Research site
Kawasaki, Kanagawa, Japan
Research site
Yokohama, Kanagawa, Japan
Research site
Chuo-Ku, Kumamoto, Japan
Research site
Tsu, Mie-ken, Japan
Research site
Isahaya, Nagasaki, Japan
Research site
Ōmura, Nagasaki, Japan
Research site
Sasebo, Nagasaki, Japan
Research site
Tenri, Nara, Japan
Research site
Yufu, Oita Prefecture, Japan
Research site
Kurashiki, Okayama-ken, Japan
Research site
Nakagami, Okinawa, Japan
Research site
Abeno-Ku, Osaka, Japan
Research site
Sakai, Osaka, Japan
Research site
Ōmiya, Saitama, Japan
Research site
Hamamatsu, Shizuoka, Japan
Research site
Shimotsuke, Tochigi, Japan
Research site
Kiyose, Tokyo, Japan
Research site
Minato-Ku, Tokyo, Japan
Research site
Mitaka, Tokyo, Japan
Research site
Ōta-ku, Tokyo, Japan
Research site
Shinagawa-Ku, Tokyo, Japan
Research site
Shinjuku-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.